http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4096685-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e731cd5fa7555d2c1822390f6137ba5a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
| filingDate | 2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_317c949f9b92525bddf844ff390f409e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d80046ece187a1aeeb4ad4d245b0541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35e8987bcda8fabf73f65a9a5625aed3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6c92fb3747f2028408038ddaf77150a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be35f962787d3562e1eb0414de4d48b3 |
| publicationDate | 2022-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-4096685-A1 |
| titleOfInvention | Beta-glucan for use in modulation of an immune response in a remission |
| abstract | The invention discloses a use of beta-glucan in order to increase anti-tumor immunity in remission after the treatment of solid tumors, where after the long-term peroral usage the concentration of the CD8+ lymphocytes, CD19+ lymphocytes increases and the level of lgG3, IgA, CD16+56+ increases. The clinical study has shown the efficiency of the preventive treatment during the immunosensitive cancer such as breast cancer. In the preferable arrangement beta-glucan is fungal β (1,3/1,6) glucan prepared from the oyster mushroom. During the sequential usage in the first phase a high dose of beta-glucan is used and in the second phase a low dose of beta-glucan is used, whereby the high dose of beta-glucan is at least twice the low dose of beta- glucan. The administration is long-term and continuous without sequences where the dosage is completely omitted. The high dose of beta-glucan can daily range from 600 mg to 800 mg, preferably 700 mg and low dose of beta-glucan can daily range from 50 mg to 300 mg, preferably 100 mg or 200 mg. |
| priorityDate | 2020-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.